Roche drug cocktail doubles chance of holding lung cancer at bay
ZURICH (Reuters) – Adding Roche’s immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts on Thursday labeled unprecedented. Source: Reuters Medical News